Market cap
$109 Mln
Revenue (TTM)
$18 Mln
P/E Ratio
--
P/B Ratio
5.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -92.53 | -98.76 | -50.80 | -20.64 | 0.44 |
| EBIT | 15.80 | -340.07 | -1,193.34 | -296.98 | -271.69 |
| Net Profit | 15.51 | -390.21 | -2,206.37 | -422.26 | -284.49 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Jul-22 | Jul-21 |
| EBIT-Margin
| 11.55 | -54.61 | -176.58 | 12.68 | -7.87 |
| Net Margin
| -- | -- | -186.63 | -- | -- |
| Return on equity
| 15.73 | -55.71 | -110.73 | 7.31 | -5.33 |
| Return on Capital
| 14.94 | -55.62 | -- | 5.08 | -4.15 |
| Return on Assets
| 11.39 | -28.68 | -42.68 | 4.59 | -3.69 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.36 | 0.53 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
--
|
5.08
|
-4.15
|
43.90
|
-122.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-110.73
Lower than Peers by 84.42
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-110.73
|
7.31
|
-5.33
|
45.22
|
-125.72
|
|
Peer Median
|
-26.31
|
--
|
--
|
--
|
--
|
ROA
-42.68
Lower than Peers by 29.72
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-42.68
|
4.59
|
-3.69
|
33.28
|
-72.13
|
|
Peer Median
|
-12.96
|
--
|
--
|
--
|
--
|
EBIT Margin
-176.58
Lower than Peers by 116.88
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-176.58
|
12.68
|
-7.87
|
29.86
|
-156.47
|
|
Peer Median
|
-59.70
|
--
|
--
|
--
|
--
|
Net Margin
-186.63
Lower than Peers by 115.57
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-186.63
|
7.39
|
-6.79
|
30.32
|
-156.85
|
|
Peer Median
|
-71.06
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-50.80
Lower than Peers by 71.35
Year on year growth in net sales
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-50.80
|
0.49
|
-0.28
|
1.83
|
-0.03
|
|
Peer Median
|
20.56
|
--
|
--
|
--
|
--
|
EBIT Growth
-1,193.34
Lower than Peers by 1,208.54
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-1,193.34
|
339.41
|
-118.89
|
153.99
|
--
|
|
Peer Median
|
15.20
|
--
|
--
|
--
|
--
|
Net Profit Growth
-2,206.37
Lower than Peers by 2,214.23
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-2,206.37
|
261.64
|
-116.06
|
154.70
|
--
|
|
Peer Median
|
7.86
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
--
|
0.36
|
0.53
|
0.02
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.10
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
0.10
|
0.01
|
0.01
|
0.02
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
5.48
Higher than Peers by 1.99
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
5.48
|
10.10
|
9.21
|
7.00
|
2.99
|
|
Peer Median
|
3.48
|
--
|
--
|
--
|
--
|
Quick Ratio
5.48
Higher than Peers by 2.19
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
5.48
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.29
|
--
|
--
|
--
|
--
|
Interest Coverage
-18.25
Lower than Peers by 16.74
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-18.25
|
2.42
|
-16.46
|
26.08
|
-146.13
|
|
Peer Median
|
-1.51
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
0.23
Lower than Peers by 24.10
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
0.23
|
32.73
|
32.52
|
18.88
|
33.22
|
|
Peer Median
|
24.33
|
--
|
--
|
--
|
--
|
Asset Turnover
0.23
Lower than Peers by 0.00
Sales / Average Total Assets
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
0.23
|
0.62
|
0.54
|
1.10
|
0.46
|
|
Peer Median
|
0.23
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
--
|
99.72
|
107.50
|
55.92
|
121.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
--
|
127.63
|
126.23
|
57.95
|
277.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
5.09
Higher than Peers by 0.13
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
5.09
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.79
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
-2.79
|
-6.15
|
28.61
|
-2.59
|
1.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
109
Higher than Peers by 25
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Jul-22
|
Jul-21
|
Jul-20
|
Jul-19
|
|---|---|---|---|---|---|
|
Opiant Pharmaceuticals (OPNT)
|
109
|
--
|
--
|
--
|
--
|
|
Peer Median
|
83
|
--
|
--
|
--
|
--
|